The Drive for Best Practice in Biopharmaceutical Manufacturing - Introducing a new way to think about sharing information in a patent-driven industry. - BioPharm International

ADVERTISEMENT

The Drive for Best Practice in Biopharmaceutical Manufacturing
Introducing a new way to think about sharing information in a patent-driven industry.


BioPharm International
Volume 25, Issue 2, pp. 53-54


Simon Chalk
Best practice means finding and using the best ways of working to achieve strategic and operational goals. This is an important concept for biopharmaceutical manufacturing as much as it is for other industries. Notably, biopharmaceutical businesses work within a regulatory framework that requires good practices (GxP) to be defined and consistently executed. So, are good practices the same as best practices?

Demonstrating good manufacturing practice (GMP) represents a minimum requirement to run biopharmaceutical operations. Failure to comply with GMP, on the other hand, can lead to external intervention and remedial actions, at high cost and risk to reputation. But good practice is not necessarily the same as best practice and regulations do not cover the whole gamut of business processes and systems that affect performance. Much of the good practices used can be described as being "acceptable" to external inspectors, but in most cases, there are better ways of working that still earn regulatory approval.

Is the industry doing enough to proactively search out, internalize, and establish better practices? Or do we mostly allow good or acceptable practice to stay unchallenged and unimproved? In today's tough environment, biopharmaceutical manufacturers cannot afford to ignore the fact that better ways of working might be possible.

People engaged in biopharmaceutical operations, whether it is production, quality, development, or engineering have a great appetite for learning and sharing their approaches. Such sharing can be achieved in many ways: reading technical journals, attending conferences, networking with peers, and participating in structured knowledge sharing and Operational Excellence programs. Senior management must encourage these initiatives.

Concerns about sharing information with competitors has be put in perspective, however. When companies collaborate, the industry is strengthened and competition is increased. Most importantly, collaboration supports increased quality and patient safety. These benefits easily outweigh the potential loss of advantage where some companies incur higher costs from using poorer practices. There is no real competitive advantage here. Sharing best practice does not mean sharing IP, cost, or commercial information. These are no-go areas.

In a sharing-based environment, most information can be gleaned from other parts of the business or from other companies in the industry. Less common practice is to seek out other industries to learn about their best practices or benchmark their performance levels. And here's the problem: if most of our best-practice sharing is within our company or within similar companies, then we miss out on learning where significant gains can be made. As one senior executive put it to me, "If I'm a C-grade student, I don't just want to learn from a C+ grade friend. I also want to learn from the A-grade student who is going to help me leap forward."

Sharing best practice between players in the industry means improvement comes more quickly. However, if the best practice doesn't exist in the industry how can it be shared and copied? Taking best practice from other industries can bring a step-change in perspective and in performance.

A great example spreading across our industry at the moment are practices associated with people making mistakes in their work and how the resulting problems are dealt with. When mistakes lead to product quality risks, then there is a duty on the part of the manufacturer to identify, correct, and prevent the mistakes from reoccurring. Until recently, the common practice for responding to human error was to retrain the person making the mistake. If this is done correctly and documented, then it is acceptable from a GMP perspective. Good practice? Yes, but is it best practice?

The nature of bioprocessing necessitates a significant amount of manual intervention and the amount of reported human errors in GMP investigations is high. These errors are costly to the industry not only in terms of rework, lost product, and lead time but also in terms of the number of errors that implicate training, supervision, verification, and attention to detail. In such instances, the ability of the industry to identify and address true root causes is questioned. As a result, regulatory concerns have been heightened, and agencies are pushing for a more formal approach to Human Error Reduction (HER).

The shifting environment suggests that past good practice may not be future acceptable practice. So how can better practices associated with human error be found and used?

One only has to look at nuclear or aerospace businesses to realize there are better ways. The worst-case impact of human error in these industries doesn't need to be detailed here, but it is worth mentioning that millions of hours of operation are routinely recorded without accident. Best practices found in nuclear and aerospace operations include the following:

  • Near misses are recorded and investigated as learning opportunities.
  • Management encourages the highlighting of errors to facilitate improvement rather than punish the guilty.
  • Systemic issues are reviewed for root cause analysis and true preventive measures adopted.
  • Environmental, behavioral, and psychological factors are assessed in a structured way.

These practices have been largely absent in pharmaceuticals. However, there is now a rapid uptake in these ways of working and implementation is active in many biopharmaceutical businesses.

At the end of this month, February 2012, 12 top biopharmaceutical businesses will meet in London to compare and contrast HER approaches. The aim is to create a common level of awareness of how the industry is effectively addressing human errors, accelerating the journey by learning from other regulated industries whose HER approaches are mature and to develop an industry vision for best practice HER. This will be only be the start of an ongoing collaboration to make sure biopharmaceutical manufacturing is as reliable as any other safety critical business across the world.

The demands on biopharmaceutical operations for better performance will not go away—in fact, they will increase. All means must be explored to accelerate the improvement process, including shamelessly copying from the best and borrowing from (and giving to) others. Best-practice sharing will itself become a best practice feature of the most successful organizations involved in biopharmaceutical innovation and production.

Simon Chalk is director of the BioPhorum Operations Group,

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here